X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   MYLAN
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
MYLAN
Dec-14
ALEMBIC PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7923,830-   
Low Rs4432,699-   
Sales per share (Unadj.) Rs167.01,311.3-  
Earnings per share (Unadj.) Rs38.2158.0-  
Cash flow per share (Unadj.) Rs42.0254.3-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9651.9-  
Shares outstanding (eoy) m188.52378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.72.5 148.5%   
Avg P/E ratio x16.220.7 78.3%  
P/CF ratio (eoy) x14.712.8 114.5%  
Price / Book Value ratio x7.35.0 145.2%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3831,235,346 9.4%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m4,2140-   
Avg. sales/employee Rs ThNM19,846.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,390.8-  
INCOME DATA
Net Sales Rs m31,487496,164 6.3%  
Other income Rs m55-2,892 -1.9%   
Total revenues Rs m31,542493,272 6.4%   
Gross profit Rs m10,060123,398 8.2%  
Depreciation Rs m72236,441 2.0%   
Interest Rs m3721,402 0.2%   
Profit before tax Rs m9,35662,663 14.9%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1602,635 82.0%   
Profit after tax Rs m7,19459,771 12.0%  
Gross profit margin %31.924.9 128.5%  
Effective tax rate %23.14.2 549.1%   
Net profit margin %22.812.0 189.7%  
BALANCE SHEET DATA
Current assets Rs m15,066436,194 3.5%   
Current liabilities Rs m7,674341,017 2.3%   
Net working cap to sales %23.519.2 122.4%  
Current ratio x2.01.3 153.5%  
Inventory Days Days6778 85.8%  
Debtors Days Days41107 37.9%  
Net fixed assets Rs m8,237114,786 7.2%   
Share capital Rs m37717,546 2.1%   
"Free" reserves Rs m15,4160-   
Net worth Rs m16,005246,643 6.5%   
Long term debt Rs m0368,460 0.0%   
Total assets Rs m24,594993,454 2.5%  
Interest coverage x255.23.9 6,498.1%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.30.5 256.3%   
Return on assets %29.48.2 359.8%  
Return on equity %44.924.2 185.5%  
Return on capital %58.713.6 430.6%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Net fx Rs m12,4930-   
CASH FLOW
From Operations Rs m9,30465,221 14.3%  
From Investments Rs m-3,105-51,435 6.0%  
From Financial Activity Rs m-1,959-17,186 11.4%  
Net Cashflow Rs m4,240-3,400 -124.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: ELDER PHARMA  ALEMBIC LTD  UNICHEM LAB  CIPLA  SANOFI INDIA  



Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 20, 2018 09:47 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - WOCKHARDT LTD. COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS